CLEC10A 是一种 C 型凝集素受体，专门标记传统树突细胞亚群二和三（cDC2 和 DC3）。它具有独特的聚糖抗原识别特征，末端 N-乙酰半乳糖胺残基经常存在于肿瘤微环境中。尽管 CLEC10A 表达允许精确靶向 cDC2 和 DC3 来治疗癌症，但 CLEC10A 信号传导也与促进肿瘤生长的抗炎反应相关。在这里，我们回顾了 CLEC10A 参与肿瘤的潜在益处和缺点微环境。我们讨正确的配体呈递和佐剂组合将是关键。

CLEC10A is a C-type lectin receptor that specifically marks the conventional dendritic cell subsets two and three (cDC2 and DC3). It has a unique recognition profile of glycan antigens, with terminal N-Acetylgalactosamine residues that are frequently present in the tumor microenvironment. Even though CLEC10A expression allows for precise targeting of cDC2 and DC3 for the treatment of cancer, CLEC10A signaling has also been associated with anti-inflammatory responses that would promote tumor growth.Here, we review the potential benefits and drawbacks of CLEC10A engagement in the tumor microenvironment. We discuss the CLEC10A-mediated effects in different cell types and incorporate the pleiotropic effects of IL-10, the main anti-inflammatory response upon CLEC10A binding.To translate this to a successful CLEC10A-mediated immunotherapy with limited tumor-promoting capacities, finding the right ligand presentation and adjuvant combination will be key.